<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Strict <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy for thoracic <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> is extremely important </plain></SENT>
<SENT sid="1" pm="."><plain>Administration of beta-blocker or <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker (ARB) has been reported to prevent <z:hpo ids='HP_0002617'>aneurysm</z:hpo> enlargement in patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>While there is no significant association between <z:hpo ids='HP_0000822'>hypertension</z:hpo> and the risk of development of <z:hpo ids='HP_0004953'>abdominal aortic aneurysm</z:hpo>, a large-scale case controlled study showed a lower frequency of ruptured <z:hpo ids='HP_0002617'>aneurysm</z:hpo> in patients treated with <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The beneficial effects of <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> and/or ARB treatment should be confirmed by large-scale randomized controlled-trials </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo>, administration of beta-blockers has been considered to exacerbate lower limb ischemic symptoms; however they have recently been shown to be used safely in patients exhibiting <z:hpo ids='HP_0004417'>intermittent claudication</z:hpo> </plain></SENT>
</text></document>